INTERCEPT and Blood Safety

How does INTERCEPT improve blood safety?

The process of pathogen reduction by inactivation that INTERCEPT™ employs is a proactive safety measure – the process can neutralise clinically relevant pathogens present in platelet, plasma and red blood cell components independently of whether they have been identified as specific blood supply risks. This is critical because there is typically a lag between the emergence of new pathogens, and the recognition that an additional safety intervention may be needed.

For platelet components, the most important potential benefit of INTERCEPT has been proven to be a reduction in the risk of bacterial contamination and sepsis, a major source of patient morbidity and mortality despite the implementation of multiple interventions.

In addition, INTERCEPT reduces the number of active T-cells to a level that potentially lowers the risk of transfusion-associated graft versus host disease (TA-GVHD).


2006-2011: Sweeney J, Lozano M. Platelet Transfusion Therapy. Bethesda: AABB Press, 2013.
2012-2014: French National Agency for Medicine and Health Product Safety/ANSM, Hemovigilance Activity Reports.
SwissMedic Haemovigilance Annual Reports
Cazanave, J. et al. 2011, Osselaer et al.,2009, Osselaer Cazenave Vox Sang 2008; Osselaer et al Transfusion 2008; Corash et al. manuscript in preparation, Van Haute, 2007,Schlencke et al. 2011, Infanti et al. 2011, Siegle et al. 2012, 2009 Afsapps/ANSM Reports 2006-2011, SwisMedic report 2011